Hepatocellular Carcinoma Clinical Trials in Orange, California

7 studies are recruiting for hepatocellular carcinoma in Orange, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

   This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT05497531 on ClinicalTrials.gov

2. Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

   The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California

   Locations

   54 in total

   Run by

   Pfizer

   See if you can join NCT07227012 on ClinicalTrials.gov

3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

4. Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

   This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT04472767 on ClinicalTrials.gov

5. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

   The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California Irvine Medical Center, Orange, California

   Locations

   21 in total

   Run by

   Tvardi Therapeutics, Incorporated

   See if you can join NCT05440708 on ClinicalTrials.gov

6. Combination of TATE and PD-1 Inhibitor in Liver Cancer

   This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellula…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   University of California, Irvine, Orange, California

   Locations

   3 in total

   Run by

   Teclison Ltd.

   See if you can join NCT03259867 on ClinicalTrials.gov

7. A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

   Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UC Irvine /ID# 255673, Orange, California

   Locations

   37 in total

   Run by

   AbbVie

   See if you can join NCT06109272 on ClinicalTrials.gov